MER511 not checked

Merida Biosciences

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will receive multiple ascending doses of MER511 via SC administration assigned for their cohort on Day 1 and Day 29”In the company’s words, NCT07305818 on ClinicalTrials.gov
Tested for
Graves Disease
Main trialPhase 1
“The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.”In the company’s words, NCT07305818 on ClinicalTrials.gov

Other drugs for Graves Disease

All 25 drugs for Graves Disease

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 24 Jul 2028 NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow MER511

Following is part of Solo: you see every change to MER511 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in